SPRB NASDAQ
Credit Risk of going bust: higher than 68% of companies Debt: 5.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.57 (down 99%), Spruce Biosciences, Inc. would be worth roughly what it owes.
Total debt $7.7M against a stock market value of $126.4M.
Distance to default 3.57 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.8M (short-term plus half of long-term), stock volatility 87.1%; Altman Z'' -2.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Quartel Adrian W | A-Award | 13,000 | — | 2026-07-27 |
| Quartel Adrian W | 0 | — | 2026-07-27 | |
| SPIEGELMAN DANIEL K | A-Award | 1,700 | $52.70 | 2026-05-21 |
| SIMPSON CAMILLA V | A-Award | 1,700 | $52.70 | 2026-05-21 |
| GREY MICHAEL G | A-Award | 1,700 | $52.70 | 2026-05-21 |